Abstract 190P
Background
The combination of gemcitabine and nab-paclitaxel (GnP) has been established as the first-line chemotherapy in patients (pts) with metastatic pancreatic cancer (M-PC). However, the efficacy of the therapy in pts with borderline resectable PC (BR-PC) and locally advanced PC (LA-PC) is not clear. Although achieving R0 resection is one of the main target for these pts, the details of the response, such as the best time to evaluate the response is not clear. Therefore, we evaluated the details of response with GnP treatment.
Methods
We retrospectively reviewed the medical records of pts with BR-PC, LA-PC, and M-PC who received GnP as the first-line chemotherapy between January 2016 and April 2019 at six hospitals. We investigated time to response (TTR), duration of response (DoR), and depth of response (DpR). The response of the primary tumor and the metastases were evaluated separately in pts with M-PC. The response of the primary tumor was evaluated in all pts.
Results
A total of 47 pts were analyzed; the median age was 70 years, male was 66% and the number of pts with BR-PC/LA-PC/M-PC was 6%/26%/68%. The response rates of primary tumor and metastases were 40% and 31%, respectively. Among the pts with M-PC, seven had a partial response (PR) of the primary tumor without PR of metastases. The median TTR and time to best response of the primary tumor and metastases were 3.17 months (m) and 4.21 m (p = 0.191), and 4.11 m and 5.88 m (p = 0.724), respectively. The median DoR of the primary tumor and metastases were 5.36 m and 4.11 m, respectively (p = 0.277). The median DpR of the primary tumor and metastases were 28.3% and 15.3%, respectively (p = 0.733). The median progression-free survival and overall survival in M-PC pts with and without PR of the primary tumor were 8.48 m and 6.41 m (p = 0.267), and 14.72 m and 7.66 m (p = 0.186), respectively.
Conclusions
The response of the primary tumor tended to be higher and earlier than that of the metastases. A favorable efficacy was observed in pts with BR-PC and LA-PC as well as pts with M-PC. This study indicated that the best time to evaluate the response of the primary site to consider the conversion therapy was around 4 m. Pts with M-PC showing PR of the primary tumor tended to have a favorable prognosis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
154P - Genetic characteristics of participants in the Australian Pancreatic Screening Study
Presenter: Krithika Murali
Session: Poster display session
Resources:
Abstract
155P - Mean Platelet Volume (MPV) is it a new prognostic marker in resectable carcinoma stomach?
Presenter: Girish M. S
Session: Poster display session
Resources:
Abstract
156P - A positive feedback between IDO1 metabolite and COL12A1 via MAPK pathway to promote gastric cancer metastasis
Presenter: Zhen Xiang
Session: Poster display session
Resources:
Abstract
157P - Lymph node ratio (LNR) a better prognostic factor after D2 gastrectomy
Presenter: Jitin Yadav
Session: Poster display session
Resources:
Abstract
158P - A clinical significance of preoperative C-reactive protein/albumin ratio in patients with extrahepatic bile duct cancer
Presenter: Kim Jinkook
Session: Poster display session
Resources:
Abstract
159P - The relation between obesity and cancer of gastrointestinal tract in Korea: The data from Statistic Korea between 2001 and 2016
Presenter: Hee Man Kim
Session: Poster display session
Resources:
Abstract
160P - Clinical outcomes of second-line chemotherapy after progression on nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic adenocarcinoma
Presenter: Jooyoung Ha
Session: Poster display session
Resources:
Abstract
161P - Chitinase 3-Like 1 gene (T/C) polymorphism and serum YKL-40 in hepatocellular carcinoma
Presenter: Alshimaa Alhanafy
Session: Poster display session
Resources:
Abstract
162P - Hypofractionated radiotherapy for pulmonary metastases from hepatocellular carcinoma: Treatment response and prognostic factors affecting survival
Presenter: In Young Jo
Session: Poster display session
Resources:
Abstract
163P - Excision repair cross-complementation group 1 and 2 (ERCC1/2) Single nucleotide polymorphisms and chemotherapy treatment outcome in Cholangiocarcinoma
Presenter: Thanachai Sanlung
Session: Poster display session
Resources:
Abstract